PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-74.25%
Both yoy net incomes decline, with VET at -36.16%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-1.52%
Negative yoy D&A while VET is 0.52%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
94.57%
Some yoy growth while VET is negative at -97.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
350.00%
SBC growth well above VET's 19.16%. Michael Burry would flag major dilution risk vs. competitor’s approach.
470.37%
Slight usage while VET is negative at -168.17%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
470.37%
Some yoy usage while VET is negative at -168.17%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
268.18%
Well above VET's 109.84%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
68.77%
Some CFO growth while VET is negative at -11.64%. John Neff would note a short-term liquidity lead over the competitor.
-0.31%
Both yoy lines negative, with VET at -83.37%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-83.65%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
3013.64%
Purchases growth of 3013.64% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-91.24%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
3.68%
Less 'other investing' outflow yoy vs. VET's 159.35%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-43.80%
We reduce yoy invests while VET stands at 36.01%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
100.00%
Debt repayment similar to VET's 100.00%. Walter Schloss sees parallel liability management or similar free cash flow availability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.